PATRICK GREGORY S 4
4 · SUPERNUS PHARMACEUTICALS INC · Filed Feb 28, 2019
Insider Transaction Report
Form 4
PATRICK GREGORY S
VP, Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2019-02-27$9.13/sh+20,000$182,600→ 67,896 total - Sale
Common Stock
2019-02-27$41.53/sh−20,000$830,650→ 47,896 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-02-27−20,000→ 15,000 totalExercise: $9.13Exp: 2025-03-03→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted November 28, 2018.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.0000 to $42.1900, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vests in four equal annual installments beginning on March 3, 2016.